Vertex Pharmaceuticals: the signal cools
Vertex Pharmaceuticals slips 1.7% and closes below the trade's first stop level
Vertex Pharmaceuticals: the signal cools
Our view last week
Vertex Pharmaceuticals closed the week almost flat (+0.1%), after last week's -8.1% giveback: price carved a fresh double bottom in the 434 area, with a 4% intermediate rebound, but sellers still rule the tape — barely a quarter of the volume is on the buy side. The buy signal, now in its fourth week, is showing the first signs of fading: strength drops to 66 out of 100. The trade is still up 7.5%, with earnings 2 weeks away adding a note of caution.
This week's summary
Vertex Pharmaceuticals shares bounce 3% off the 50-day moving average, in the 470 area, after a touch near 465, but the week still closes down 1.7% and the buy signal, now in its fifth week, is losing steam: strength drops to 66 out of 100. Price closed below the first stop level (SL1) flagged in last week's card (area 477.4): for anyone following that level the trade is closed.
IQS Phase
63
ordinary
Signal Strength
66
medium
Sizing
STANDARD
Ranking
#30 / 124
US stocks in progress
Trade P&L %
+5.70%
from signal to date, no stop loss
Rank position
ranks 30th among the 124 Longs already running for US stocks in our ranking, with a signal strength of 66 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly +0.92% · monthly +6.01%
VRTX belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content